Who
Krishnaswamy Yeleswaram
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Rapport Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $8.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Jun 2024
- Last trade
- 25 Aug 2026
- Last filed
- 26 Aug 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M20,799 at $50.31 | filing |
| 25 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $827K16,201 at $51.06 | filing |
| 25 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M20,799 at $50.31 | filing |
| 25 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $827K16,201 at $51.06 | filing |
| 24 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $658K13,160 at $50.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $658K13,160 at $50.00 | filing |
| 19 Aug 2026filed 20 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K404 at $49.90 | filing |
| 19 Aug 2026filed 20 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $20K404 at $49.90 | filing |
| 17 Apr 2026filed 21 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $809K20,225 at $39.99 | filing |
| 17 Apr 2026filed 21 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $809K20,225 at $39.99 | filing |
| 14 Apr 2026filed 14 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K10,200 at $35.08 | filing |
| 14 Apr 2026filed 14 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K10,200 at $35.08 | filing |
| 13 Apr 2026filed 14 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $321K9,165 at $34.97 | filing |
| 13 Apr 2026filed 14 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $321K9,165 at $34.97 | filing |
| 10 Apr 2026filed 14 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K500 at $34.98 | filing |
| 10 Apr 2026filed 14 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K500 at $34.98 | filing |
| 8 Apr 2026filed 9 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K360 at $34.90 | filing |
| 8 Apr 2026filed 9 Apr 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K360 at $34.90 | filing |
| 25 Mar 2026filed 26 Mar 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $303K10,115 at $29.99 | filing |
| 25 Mar 2026filed 26 Mar 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $303K10,115 at $29.99 | filing |
News
Insider Buying: Rapport Therapeutics (NASDAQ:RAPP) Director Purchases $99,617.60 in StockRAPP · dailypolitical.com · 25 Oct 2026Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Troy Ignelzi Acquires 5,500 SharesRAPP · dailypolitical.com · 21 Oct 2026Why Is Rapport Therapeutics Stock Trading Higher Today?RAPP · aol.com · 20 Oct 2026
0 headlines in the last 90 days name Krishnaswamy Yeleswaram; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.